Acrivon therapeutics to present data at aacr annual meeting demonstrating power of acrivon predictive precision proteomics (ap3) platform and its internally-discovered, potent wee1/pkmyt1 development candidate, acr-2316

Acr-2316, a novel, selective dual wee1 and pkmyt1 inhibitor development candidate, designed using ap3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies

ACRV Ratings Summary

ACRV Quant Ranking